MX2021007949A - Dominios de union mixtos. - Google Patents

Dominios de union mixtos.

Info

Publication number
MX2021007949A
MX2021007949A MX2021007949A MX2021007949A MX2021007949A MX 2021007949 A MX2021007949 A MX 2021007949A MX 2021007949 A MX2021007949 A MX 2021007949A MX 2021007949 A MX2021007949 A MX 2021007949A MX 2021007949 A MX2021007949 A MX 2021007949A
Authority
MX
Mexico
Prior art keywords
binding domains
variable region
mixed binding
human
mixed
Prior art date
Application number
MX2021007949A
Other languages
English (en)
Inventor
Kruif Cornelis Adriaan De
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of MX2021007949A publication Critical patent/MX2021007949A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a un dominio de unión o un multímero o una variante del mismo que comprende una región variable codificada por un ácido nucleico basado en, derivado u obtenido de un animal filogenéticamente distal de un humano, cuya región variable está emparejada con una región variable humana.
MX2021007949A 2018-12-31 2019-12-27 Dominios de union mixtos. MX2021007949A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18215995 2018-12-31
PCT/NL2019/050877 WO2020141973A1 (en) 2018-12-31 2019-12-27 Mixed binding domains

Publications (1)

Publication Number Publication Date
MX2021007949A true MX2021007949A (es) 2021-10-22

Family

ID=65030899

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007949A MX2021007949A (es) 2018-12-31 2019-12-27 Dominios de union mixtos.

Country Status (15)

Country Link
US (1) US20220073649A1 (es)
EP (1) EP3906255A1 (es)
JP (2) JP7443376B2 (es)
KR (1) KR20210110600A (es)
CN (2) CN113227132A (es)
AR (1) AR117741A1 (es)
AU (2) AU2019418280B2 (es)
BR (1) BR112021013009A2 (es)
CA (1) CA3124768A1 (es)
EA (1) EA202191448A1 (es)
IL (1) IL284353A (es)
MX (1) MX2021007949A (es)
SG (1) SG11202106705UA (es)
TW (1) TW202039548A (es)
WO (1) WO2020141973A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202009036YA (en) * 2018-03-30 2020-10-29 Merus Nv Multivalent antibody
EP3772518A1 (en) 2019-08-07 2021-02-10 Merus N.V. Modified human variable domains

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6680376B2 (en) 2000-12-08 2004-01-20 Good Biotech Corporation Process for selectively isolating avian immunoglobulins
AU784900B2 (en) 2002-06-12 2006-07-20 Good Biotech Corporation Process for selectively isolating IgY antibodies from egg yolk of an anseriform bird and IgY antibodies obtained thereby
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
JP4452884B2 (ja) 2005-03-01 2010-04-21 国立大学法人広島大学 抗体およびその利用
AU2006285850A1 (en) 2005-08-29 2007-03-08 Japan Science And Technology Agency Antibody produced using ostrich and method for production thereof
DE102007035258B3 (de) 2007-07-27 2008-11-20 Forschungszentrum Karlsruhe Gmbh Einphasiges hydraulisches Bindemittel, Verfahren zu seiner Herstellung und mit diesem Bindemittel hergestellter Baustoff
CA2721093A1 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
SI3456190T1 (sl) 2008-06-27 2022-06-30 Merus N.V. Transgena mišja živali, ki proizvaja protitelesa
CA2735020A1 (en) * 2008-08-29 2010-03-04 Symphogen A/S Method for cloning avian-derived antibodies
PT2606064E (pt) * 2010-08-16 2015-06-08 Novimmune Sa Processos para a geração de anticorpos poliespecíficos e polivalentes
US20140317765A1 (en) 2011-09-01 2014-10-23 Synageva Biopharma Corp. Transgenic birds that produce chimeric human immunoglobulins
NZ772318A (en) 2012-04-20 2023-06-30 Merus Nv Methods and means for the production of ig-like molecules
AU2014218915B2 (en) * 2013-02-20 2017-01-19 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
US11033009B2 (en) 2015-08-27 2021-06-15 Crystal Bioscience Inc. Transgenic chicken for production of antibodies having a common light chain
LT3365373T (lt) * 2015-10-23 2021-05-25 Merus N.V. Surišančios molekulės, kurios inhibuoja vėžio augimą
SG11202009036YA (en) 2018-03-30 2020-10-29 Merus Nv Multivalent antibody

Also Published As

Publication number Publication date
AU2022287551A1 (en) 2023-02-02
WO2020141973A1 (en) 2020-07-09
EA202191448A1 (ru) 2021-11-19
JP7443376B2 (ja) 2024-03-05
TW202039548A (zh) 2020-11-01
JP2024014897A (ja) 2024-02-01
US20220073649A1 (en) 2022-03-10
CN114249823A (zh) 2022-03-29
IL284353A (en) 2021-08-31
SG11202106705UA (en) 2021-07-29
AU2019418280B2 (en) 2023-01-05
JP2022520707A (ja) 2022-04-01
AU2019418280A1 (en) 2021-07-08
EP3906255A1 (en) 2021-11-10
BR112021013009A2 (pt) 2021-09-14
AR117741A1 (es) 2021-08-25
KR20210110600A (ko) 2021-09-08
CA3124768A1 (en) 2020-07-09
CN113227132A (zh) 2021-08-06

Similar Documents

Publication Publication Date Title
WO2019224718A3 (en) Psma binding agents and uses thereof
PH12020552229A1 (en) Il-11ra antibodies
AU2018338314A1 (en) Protein degraders and uses thereof
PH12020552232A1 (en) IL-11 Antibodies
EA201891028A1 (ru) Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv
EA201890175A1 (ru) Антитела к cd40
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
CY1122283T1 (el) Συνδυασμος ενος αντισωματος cd30xcd16a με ενα ανταγωνιστικο αντισωμα αντι-pd-1 για θεραπεια
EA201890382A1 (ru) Конструкции антител для cd70 и cd3
CR20210154A (es) Moléculas de unión a antígeno bioespecíficas que comprenden el clon 212 anti-fap
EP4299595A3 (en) Compositions and methods related to engineered fc constructs
EP4276116A3 (en) Bispecific antibody constructs for cdh3 and cd3
EP3957723A3 (en) Engineered ligase variants
MX2018010971A (es) Compuestos y métodos para modular la tirosina cinasa de bruton.
EA201691795A1 (ru) Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина
EP3823986A4 (en) USE OF ANTIBODIES DIRECTED AGAINST SEQUENCE FAMILY 19, ELEMENT A5, FOR THE TREATMENT OF NEUROPATHIC PAIN
MX2021007949A (es) Dominios de union mixtos.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
MX2018012671A (es) Combinacion, usos terapeuticos y usos profilacticos.
WO2020123330A3 (en) Anti-alpha-synuclein antibodies and uses thereof
MX2021004925A (es) Variantes de adn-polimerasa modificadas.
WO2018183692A8 (en) VECTORS AND COMPOSITIONS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
EA201992348A1 (ru) АНТИГЕН-СВЯЗЫВАЮЩИЕ БЕЛКИ, ВЗАИМОДЕЙСТВУЮЩИЕ С Jagged1
MX2021000280A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
MX2021000287A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.